CTU2: A Potential Drug Target and Biomarker (G348180)

Target Name: CTU2

NCBI ID: G348180

CTU2

CTU2: A Potential Drug Target and Biomarker

Introduction

CTU2 (Cytoplasmic tRNA 2-thiolation protein 2) is a protein that plays a crucial role in the regulation of protein translation in the cytoplasm of eukaryotic cells. It is a member of the tRNA 2-thiolation family, which is involved in the modification of tRNA stability and quality. The dysfunction of CTU2 has been implicated in various diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD). As a result, identifying and targeting CTU2 as a drug target or biomarker has become an attractive idea in the scientific community.

The tRNA 2-thiolation family consists of four proteins: ITU2 (ISOform 1), ITU3 (ISOform 2), ISI2 (ISOform 3), and CTU2 (ISOform 1). These proteins share a common domain that contains a nucleotide-binding oligomerization domain (NBO), which is responsible for binding to specific tRNPs. In addition to the NBO, each protein has unique amino acid residues that are involved in the modification of tRNA stability and quality.

CTU2 is a 120-kDa protein that is expressed in various tissues and cells, including muscle, heart, brain, and cancer cells. It is primarily localized to the cytoplasm and is involved in the regulation of protein translation efficiency. Several studies have shown that CTU2 is involved in the modulation of tRNA stability and quality, including the addition of 2-thiol groups to specific tRNA sequences. These 2-thiol groups can interact with various cellular components, including the nuclear glycosome (40), the ribosome (34 ), and the microtubules.

The dysfunction of CTU2 has been implicated in various diseases, including cancer, neurodegenerative diseases, and COPD. For example, studies have shown that high levels of CTU2 are associated with poor prognosis in patients with pancreatic cancer, and that inhibition of CTU2 has been shown to enhance the efficacy of radiation therapy in these patients. Additionally, animal models of neurodegenerative diseases, such as dopamine-dependent Parkinson's disease and amyloid neurodegeneration, have shown that mice with reduced or absent CTU2 have reduced neurotoxicity and improved survival rates.

Furthermore, some studies have suggested that CTU2 may be a potential biomarker for COPD. The cytoplasmic expression of CTU2 has been shown to be decreased in individuals with severe COPD, and knockdown of CTU2 has been shown to exacerbate the symptoms of this disease. Additionally, studies have shown that individuals with poor aerobic fitness have lower levels of CTU2 in their muscle tissue, which may be related to increased demand for protein translation services by the muscle fibers.

In conclusion, CTU2 is a protein that is involved in the regulation of protein translation in the cytoplasm of eukaryotic cells. Its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and COPD. As a potential drug target or biomarker, CTU2 has received significant attention from the scientific community, and further studies are needed to fully understand its role in these diseases.

Protein Name: Cytosolic Thiouridylase Subunit 2

Functions: Plays a central role in 2-thiolation of mcm(5)S(2)U at tRNA wobble positions of tRNA(Lys), tRNA(Glu) and tRNA(Gln). May act by forming a heterodimer with CTU1/ATPBD3 that ligates sulfur from thiocarboxylated URM1 onto the uridine of tRNAs at wobble position

The "CTU2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTU2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets